TY - JOUR
T1 - Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gsα
AU - Gould, Thomas J.
AU - Bizily, Scott P.
AU - Tokarczyk, Jan
AU - Kelly, Michele P.
AU - Siegel, Steven J.
AU - Kanes, Stephen J.
AU - Abel, Ted
N1 - Funding Information:
We would like to thank Jennifer Davis for continued discussions about this work and David Rapoport for assistance with genotyping. This work was supported by P50 MH 6404501, Project 3 to TA (R Gur, Conte Center P.I.), NIMH K08 MH067091 to SJK, along with NIMH RO1 MH60244 and NIA RO1 AG18199, and by grants from the Whitehall Foundation, the University of Pennsylvania Research Foundation, and a Young Investigator Award from the Mental Retardation and Development Disabilities Research Center at Children’s Hospital of Philadelphia (HD26979) to TA. TA is a John Merck Scholar and a David and Lucile Packard Foundation Fellow. MPK is supported by NIMH T32 MH019112 (R. Gur, P.I.).
PY - 2004/3
Y1 - 2004/3
N2 - Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of Gsα (G sα*), the G protein that couples receptors such as the D1 and D5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G sα* and R(AB) transgenic mice. Gsα* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. Gsα* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.
AB - Schizophrenia is a complex disorder characterized by wide-ranging cognitive impairments, including deficits in learning as well as sensory gating. The causes of schizophrenia are unknown, but alterations in intracellular G-protein signaling pathways are among the molecular changes documented in patients with schizophrenia. Using the CaMKIIα promoter to drive expression in neurons within the forebrain, we have developed transgenic mice that express a constitutively active form of Gsα (G sα*), the G protein that couples receptors such as the D1 and D5 dopamine receptors to adenylyl cyclase. We have also generated mice in which the CaMKIIα promoter drives expression of a dominant-negative form of protein kinase A, R(AB). Here, we examine startle responses and prepulse inhibition of the startle reflex (PPI) in these G sα* and R(AB) transgenic mice. Gsα* transgenic mice exhibited selective deficits in PPI, without exhibiting alterations in the startle response, whereas no deficit in startle or PPI was found in the R(AB) transgenic mice. Thus, overstimulation of the cAMP/PKA pathway disrupts PPI, but the cAMP/PKA pathway may not be essential for sensorimotor gating. Gsα* transgenic mice may provide an animal model of certain endophenotypes of schizophrenia, because of the similarities between them and patients with schizophrenia in G-protein function, hippocampus-dependent learning, and sensorimotor gating.
UR - http://www.scopus.com/inward/record.url?scp=1642320064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642320064&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1300309
DO - 10.1038/sj.npp.1300309
M3 - Article
C2 - 14694347
AN - SCOPUS:1642320064
SN - 0893-133X
VL - 29
SP - 494
EP - 501
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 3
ER -